Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials

Table 1 Clinical trials for retinal and optic nerve diseases

Clinical trial	Condition	Cells	Route of administration	Dose	Estimated enrollment	Recruitment status	Study phase	Country	Start date
NCT010685611	Retinosis pigmentaria	ABMSC	Intravitreal injection	10 × 106 cells/0.1 mL	5	Completed	I	Brazil	2010
NCT01531348	Retinosis pigmentaria	ABMMSC	Intravitreal injection	1 × 106 cells/0.1 mL	10	Enrolling by invitation	I	Tailandia	2012
NCT015607152	Retinosis pigmentaria	ABMSC	Intravitreal injection	10 × 106 cells/0.1 mL	50	Recruiting	II	Brasil	2012
NCT017360593	Retinosis pigmentaria, AMD, DR,VO	ABMSC	Intravitreal injection	3.4 × 106 cells/0.1 mL	15	Enrolling by invitation	I	EEUU	2012
NCT01914913	Retinosis pigmentaria	ABMSC	-	-	15	Recruiting	I/II	India	2014
NCT02280135	Retinosis pigmentaria	ABMSC	Intravitreal injection	30 × 106 cells/0.1 mL	10	Recruiting	I	Spain	2014
NCT02709876	Retinosis pigmentaria	ABMSC	Intravitreal injection	-	50	Recruiting	I/II	Arabia	2014
NCT01518127	Stargardt’s disease and AMD	ABMSC	Intravitreal injection	10 × 106 cells/0.1 mL	10	Recruiting	I/II	Brazil	2011
NCT017360593	Stargardt’s disease,AMD, DR, VO, RP	ABMSC	Intravitreal injection	3.4 × 106 cells/0.1 mL	15	Recruiting	I	EEUU	2012
Carta al editor Act. Opht4	Diabetic retinopathy	ABMSC	Intravitreal injection	18 × 107 cells/0.5 mL	1	Completed	I	Germany	2008
NCT01518842	Diabetic retinopathy	ABMSC	Intravitreal injection	2 × 104 cells/0.1 mL	30	Unknown	I/II	Brasil	2011
IRCT201111291414N29	Diabetic retinopathy	ABMMSC	Intravenous	2 × 106 cells/kg	20	Ongoing	I/II	Iran	2011
NCT017360593	Diabetic retinopathy, VO, HRD	ABMSC	Intravitreal injection	3.4 × 106 cells/0.1 mL	15	Recruiting	I	EEUU	2012
ChiCTR-ONC-16008055	Diabetic retinopathy	ASMSC	-	-	30	Recruiting	I/II	China	2013
NCT01518127	AMD, Stargardt’s disease	ABMSC	Intravitreal injection	10 × 106 cells/0.1 mL	10	Recruiting	I/II	Brasil	2011
NCT017360593	AMD, DR, VO, HRD	ABMSC	Intravitreal injection	3.4 × 106 cells/0.1 mL	15	Recruiting	I	EEUU	2012
NCT02016508	AMD	ABMSC	Intravitreal injection	-	1	Unknown	I/II	Egypt	2013
NCT02024269	AMD	AASC	Intravitreal injection	-	-	Withdrawn	I	EEUU	2013
NCT00787722	Neuromielitis óptica	AHSC	Intravenous	-	10	Recruiting	I	EEUU	2008
NCT01364246	Neuromielitis óptica	UC-MSC	Intravenous	-	20	Unknown	I/II	China	2010
NCT01339455	Neuromielitis óptica	AHSC	Intravenous	-	3	Ongoing	I/II	Canada	2011
NCT02249676	Neuromielitis óptica	ABMMSC	Intravenous	2 × 106 cells/kg	15	Recruiting	II	China	2014
NCT02638714	Optic nerve atrophy	AHSC	-	-	100	Ongoing	I/II	Jordania	2013
NCT01834079	Optic nerve atrophy	ABMSC	Intrathecal	10 × 107 cells/dose	24	Recruiting	I/II	India	2014
ChiCTR-TRC-14005093	Traumatic optic neuropathy	UC-MSC	Endonasal	-	70	Recruiting	I/II	China	2014
NCT02330978	Glaucoma	ABMMSC	Intravitreal injection	1 × 106 cells/0.1 mL	10	Recruiting	I	Brasil	2014
NCT02144103	Glaucoma	AASC	Subtenon injection	0.5 mL	16	Enrolling by invitation	I	Russia	2014
NCT019208675	Retinal diseases, Macular degeneration, HRD, OND, glaucoma	ABMSC	Retrobulbar, subtenon, intravenous, intravitreal and intraocular injection	1.2 × 1012 cells/15 mL	300	Recruiting	I	Estados Unidos	2013

Last search performed in Clinicaltrials.gov and the International Clinical Trials Registry Platform, 18 May 2016.

¹Case reported[22];

²Case reported[23];

³Case reported[30];

⁴Case reported[28];

⁵Case reported[36,37]. ABMSC: Autologous bone-marrow stem cells; ABMMSC: Autologous bone-marrow mesenchymal stem cells; ASMSC: Autologous stromal mesenchymal stem cells; AASC: Autologous adipose stem cells; AHSC: Autologous hematopoietic stem cells; UC-MSC: Umbilical cord mesenchymal stem cells; AMD: Age-related macular degeneration; DR: Diabetic retinopathy; HRD: Hereditary retinal diseases; OND: Optic nerve diseases; RP: Retinitis pigmentosa; VO: Vein occlusions.